Solid Biosciences (SLDB) Price & Analysis

Compare

1,547 Followers

SLDB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.41 - $7.97

Previous CloseN/A

Volume1.97M

Average Volume (3M)945.98K

Market Cap

$402.58M

Enterprise Value$213.40M

Total Cash (Recent Filing)$268.11M

Total Debt (Recent Filing)$23.05M

Price to Earnings (P/E)―

Beta2.68

Next Earnings

Nov 06, 2025

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding77,869,070

10 Day Avg. Volume1,093,689

30 Day Avg. Volume945,976

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.53

Enterprise Value/Revenue68.31

Enterprise Value/Gross Profit-126.57

Enterprise Value/Ebitda-1.38

Forecast

1Y Price Target

$15.60

Price Target Upside192.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

PartnershipsSolid Biosciences announced a nonexclusive worldwide licensing and collaboration agreement with Kinea Bio, receiving an upfront payment and eligibility for additional development and sales milestones.

Regulatory ApprovalSLDB announced they have received IND/CTA clearance for SGT-501 in catecholaminergic polymorphic ventricular tachycardia (CPVT), putting them on track to have three drugs in the clinic.

Safety ProfileSGT-003 continues to be well-tolerated with no treatment-emergent serious adverse events, indicating a strong safety profile.

Bears Say

Market CompetitionSolid’s SGT-003 is well positioned to take advantage of setbacks from competitors.

Market ValuationSLDB shares are considered undervalued based on probability-adjusted SGT-003 alone, supporting an Overweight rating.

Regulatory EnvironmentInteractions with regulators regarding SGT-003 are seen as a near-term catalyst for the stock, amid the recent volatility in FDA leadership and regulatory environment.

Solid Biosciences News

Solid Biosciences announces licensing agreement with Kinea Bio

Solid Biosciences (SLDB) announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of...

1d ago

SLDB

Solid Biosciences: Strategic Collaborations and Regulatory Progress Drive Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating yesterday....

1d ago

SLDB

Solid Biosciences Gains Momentum with Promising DMD Program and Strategic Expansion

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Solid Biosciences on August 13 and set a...

1M ago

SLDB

Solid Biosciences: Promising Developments and Financial Stability Drive Buy Rating

H.C. Wainwright analyst Arthur He CFA has maintained their bullish stance on SLDB stock, giving a Buy rating...

1M ago

SLDB

Solid Biosciences Reports Increased Assets Amid Ongoing Losses

Solid Biosciences ( ($SLDB) ) has released its Q2 earnings. Here is a breakdown of the information Solid...

1M ago

SLDB

Solid Biosciences reports Q2 EPS (42c), consensus (49c)

Bo Cumbo, President and CEO of Solid, commented: “With three clinical-stage programs for neuromuscular and cardiac diseases, Solid...

1M ago

SLDB

Solid Biosciences reports inducement grants under Nasdaq listing rule

Solid Biosciences (SLDB) announced grants of 55,450 restricted stock units to four newly hired employees. The RSUs vest...

2M ago

SLDB

Solid Biosciences receives FTD from FDA for SGT-501

Solid Biosciences (SLDB) announced that it received Fast Track designation, FTD, from the U.S. Food and Drug Administration,...

2M ago

SLDB

Vor Bio appoints Cumbo, Detheux to board of directors

Vor Bio (VOR) announced the appointment of Alexander Cumbo and Michel Detheux, Ph.D., to its Board of Directors,...

2M ago

VOR

ITOS

3 Best Stocks to Buy Now, 7/14/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

BTDR

EQIX

Solid Biosciences’ Promising Advancements in Cardiac Gene Therapy: A Buy Recommendation

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SLDB stock, giving a Buy rating on...

3M ago

SLDB

Solid Biosciences: Buy Rating Backed by Regulatory Approvals and Promising Gene Therapy Pipeline

William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating today....

3M ago

SLDB

Solid Biosciences announces FDA, Health Canada approval for SGT-501 IND

Solid Biosciences (SLDB) announced approval of its investigational new drug application by the FDA and clinical trial application...

3M ago

SLDB

3 Best Stocks to Buy Now, 6/27/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3M ago

TTD

HIVE

SLDB FAQ

What was Solid Biosciences’s price range in the past 12 months?

Solid Biosciences lowest stock price was $2.41 and its highest was $7.97 in the past 12 months.

What is Solid Biosciences’s market cap?

Solid Biosciences’s market cap is $402.58M.

When is Solid Biosciences’s upcoming earnings report date?

Solid Biosciences’s upcoming earnings report date is Nov 06, 2025 which is in 43 days.

How were Solid Biosciences’s earnings last quarter?

Solid Biosciences released its earnings results on Aug 12, 2025. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.077.

Is Solid Biosciences overvalued?

According to Wall Street analysts Solid Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Solid Biosciences pay dividends?

Solid Biosciences does not currently pay dividends.

What is Solid Biosciences’s EPS estimate?

Solid Biosciences’s EPS estimate is -0.43.

How many shares outstanding does Solid Biosciences have?

Solid Biosciences has 77,869,070 shares outstanding.

What happened to Solid Biosciences’s price movement after its last earnings report?

Solid Biosciences reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went down -0.658%.

Which hedge fund is a major shareholder of Solid Biosciences?

Currently, no hedge funds are holding shares in SLDB

Solid Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.25%

Trailing 12-Months

Asset Growth

33.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Solid Biosciences

Solid Biosciences Inc. is a biotechnology company dedicated to developing transformative treatments for patients with Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration and weakness. The company's leading program focuses on gene therapy and aims to address the underlying genetic cause of DMD. Headquartered in Charlestown, Massachusetts, Solid Biosciences is at the forefront of pioneering therapies in the field of rare genetic diseases.

Solid Biosciences (SLDB) Earnings & Revenues

Historic Earnings Reports

SLDB Stock 12 Month Forecast

Average Price Target

$15.60

▲(192.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.43,6.55076923076923,7.671538461538461,8.792307692307691,9.913076923076922,11.033846153846152,12.154615384615385,13.275384615384615,14.396153846153846,15.516923076923076,16.637692307692305,17.75846153846154,18.87923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.43,6.212307692307692,6.9946153846153845,7.776923076923076,8.55923076923077,9.34153846153846,10.123846153846152,10.906153846153845,11.688461538461539,12.47076923076923,13.253076923076922,14.035384615384615,14.817692307692306,{"y":15.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.43,5.781538461538461,6.133076923076922,6.484615384615385,6.836153846153846,7.187692307692307,7.53923076923077,7.890769230769231,8.242307692307692,8.593846153846155,8.945384615384615,9.296923076923077,9.64846153846154,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >